Navigation Links
NeoGenomics to Present at Noble Financial's 5th Annual Equity Conference on Monday, June 8th
Date:6/5/2009

FT. MYERS, Fla., June 5 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM) today announced that it will present at the Fifth Annual Noble Financial Equity Conference at 9:15 AM EDT on Monday, June 8, 2009 at the Seminole Hard Rock Hotel in Hollywood, FL. Robert Gasparini, the Company's President and Chief Scientific Officer will give a presentation regarding NeoGenomics' market positioning, financial performance, and strategic direction and then answer questions from the audience. The presentation will be webcast LIVE featuring high-definition, streaming video and PowerPoint slides. Access is available by logging on to http://hosted.mediasite.com/mediasite/Viewer/?peid=a11b62efcbec4c8f90dfa8f3ca8d3cd8. In addition, a portal to the webcast will be available in the Investor Relations section of the NeoGenomics' website at http://www.neogenomics.org/investor.asp. It is recommended that interested parties register at least 10 minutes prior to the start of the presentation to ensure timely access to the webcast.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.

For more news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM where you can find a fact sheet on the company, investor presentations, and more. Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at http://www.hawkassociates.com or from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/.

About Noble Financial

Noble Financial is a privately-held, full-service capital markets firm driven by what is often overlooked by other firms - uncovering the value embedded in the orphaned, undiscovered or misunderstood company. The company focuses on converting market inefficiencies into profit opportunities. Noble Financial supports emerging companies through strategic advice, investment banking, market-making, sales & trading, comprehensive equity research, and the development of institutional support. Noble Financial's equity conferences - 2009 marks their fifth annual - allow for a unique blend of professional and personal interaction among a diverse cross-section of executives. The company has operated for 25 years and has offices in Florida, New York City and Boston.


'/>"/>
SOURCE NeoGenomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NeoGenomics, Inc. Reports First Quarter 2009 Financial Results
2. NeoGenomics Schedules its Q1 2009 Earnings Release for April 23, 2009
3. NeoGenomics Appoints Douglas M. VanOort as Executive Chairman and Interim Chief Executive Officer
4. NeoGenomics to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
5. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
6. NeoGenomics to Present at the Noble Financial Equity Conference
7. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
8. NeoGenomics Announces Results for the 3rd Quarter 2007
9. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
10. Isis Pharmaceuticals to Present at Needhams 8th Annual Life Sciences Conference
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: